The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.

Younes A, Berdeja JG, Patel MR, Flinn I, Gerecitano JF, Neelapu SS, Kelly KR, Copeland AR, Akins A, Clancy MS, Gong L, Wang J, Ma A, Viner JL, Oki Y. Lancet Oncol. 2016 Mar 31. pii: S1470-2045(15)00584-7. doi: 10.1016/S1470-2045(15)00584-7. [Epub ahead of print] PMID: 27049457 [PubMed - as supplied by publisher] READ MORE

Posted: April 28, 2016

The MMRF CoMMpass Study℠ Data Jamboree 2016

Held in Cambridge, Massachusetts, the MMRF invited over 40 attendees from various organizations to attend the MMRF CoMMpass Study Data Jamboree to discuss new findings and next steps related to the landmark CoMMpass Study℠, an initiative which is changing how researchers think about using data to drive actionable insights in the clinic. READ MORE

Posted: April 28, 2016

Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma.

Prabhala RH, Fulciniti M, Pelluru D, Rashid N, Nigroiu A, Nanjappa P, Pai C, Lee S, Prabhala NS, Bandi RL, Smith R, Lazo-Kallanian SB, Valet S, Raje N, Gold JS, Richardson PG, Daley JF, Anderson KC, Ettenberg SA, Di Padova F, Munshi NC. Leukemia. 2016 Feb;30(2):379-89. doi: 10.1038/leu.2015.228. Epub 2015 Aug 21. PMID: 26293646 [PubMed - in process] READ MORE

Posted: March 28, 2016

Page 31 of 87« First...1020...2930313233...405060...Last »